Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

Research and Innovation Action · Running

OBELISK Fighting childhood obesity to stay healthy all over the life

Coordinator
Institut National De La Sante Et De La Recherche Medicale, France
Runs
1 May 2023 to 30 April 2028
Status
Running
EU funding
€10.1m
Total cost
€10.1m
Partners
19 organisations in 10 countries
Type
Research and Innovation Action
Grant agreement
101080465

What the project is doing

In the project's own words, from its summary on CORDIS.

Obesity rates in late teens have increased in Europe from 6% in 1980 to 32%, with long-lasting effects on the prevalence of severe obesity, diabetes and cardiovascular disease, premature death and disability. Efficiently fighting adult obesity is difficult but prevention and treatment of obesity have proven to work better at young ages. OBELISK goal is to cut the roots of the pandemic of obesity in Europe targeting children first.

OBELISK is focused on elucidating, Predicting, Preventing obesity and bringing Precision medicine for children with obesity. OBELISK medicine is also Participative (4P), leveraging the potential of social innovation through engagement with families, scientific and medical communities, daycare, schools, municipalities, industries to achieve success. OBELISK objectives are: 1/ to bring breakthroughs in the molecular mechanisms by which causative factors interact to drive (or prevent) the transition from normal weight to obesity during childhood and to develop and exploit for prevention and treatment early predictive proprietary tools; 2/ to identify at least 3 novel childhood obesity genes with the prospect of identifying additional drug targets; 3/ to demonstrate the utility of targeted approaches to prevent childhood obesity; 4/ to bring breakthroughs in childhood obesity treatment including a real-life clinical study of a promising existing drug (GLP1R agonist) to reverse obesity in people with mutations predisposing to early severe obesity; 5/ to exploit the project results and disseminate best practices to prevent and treat childhood obesity, implementing education programs and translating OBELISK clinical results into guidelines and proposals for policy makers to change obesity care; 6/ to facilitate networking and exchanges with other actions and projects in order to optimize knowledge and joint activities.

OBELISK targeted approach should contribute to decrease by 35% the number of children with obesity becoming adults with obesity.

Topics

Who is involved

OrganisationCityCountryRole
Institut National De La Sante Et De La Recherche MedicaleParisFranceCoordinator
The European Childhood Obesity GroupBruxelles / BrusselBelgiumParticipant
Sib Swiss Institute of BioinformaticsGenfSwitzerlandAssociatedpartner
Deutsches Institut Fuer Ernaehrungsforschung Potsdam RehbrueckeNuthetalGermanyParticipant
Technische Universitaet MuenchenMuenchenGermanyParticipant
Fundacio Institut Hospital Del Mar D Investigacions MediquesBarcelonaSpainParticipant
Oulun YliopistoOuluFinlandParticipant
Assistance Publique Hopitaux De ParisParisFranceParticipant
Centre Hospitalier Regional Et Universitaire De LilleLilleFranceParticipant
Inserm Transfert SAParisFranceParticipant
Universite De LilleLilleFranceThird party
Azienda Ospedaliera Universitaria Integrata VeronaVeronaItalyThird party
Istituto Don CalabriaVeronaItalyThird party
Universita Degli Studi Di MessinaMessinaItalyParticipant
Universita Degli Studi Di Roma Tor VergataRomaItalyParticipant
Universita Degli Studi Di VeronaVeronaItalyParticipant
Instytut Biologii Doswiadczalnej Im. M. Nenckiego Polskiej Akademii NaukWarszawaPolandParticipant
Lunds UniversitetLundSwedenParticipant
Beta Technology LimitedSheffieldUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI